Michael Seringhaus

Michael Seringhaus is a partner at Latham & Watkins, specializing in patent litigation for life sciences and pharmaceutical companies. His practice primarily focuses on disputes involving biologics, biosimilars, small molecule pharmaceuticals, and next-generation DNA sequencing. Dr. Seringhaus leverages his scientific background, holding a Ph.D. in Molecular Biophysics & Biochemistry, to represent clients in complex intellectual property matters.

While the tracked data indicates one plaintiff-side appearance, his broader practice and notable representations demonstrate a strong focus on defending operating companies. He has experience in blocking patent attacks and challenging patent validity, as evidenced by his work for clients such as Janssen Biotech and Life Technologies. For instance, Dr. Seringhaus was part of the Latham team that successfully invalidated three patents asserted against Janssen Biotech's significant blood cancer drug, Darzalex. He also represented Life Technologies in various matters, including cases where claims were dropped in the face of summary judgment motions.

Dr. Seringhaus is active in all phases of complex patent disputes, including proceedings before the Patent Trial and Appeal Board (PTAB). He has experience litigating patent disputes in federal courts and before the PTAB, and his name appears as counsel for petitioners in inter partes review (IPR) proceedings. In addition to litigation, he provides counsel on portfolio strategy, litigation risk, and due diligence analysis.

Academically, Dr. Seringhaus earned his Ph.D. in Molecular Biophysics & Biochemistry and his J.D. from Yale University. Prior to law school, he completed a Bachelor of Science in Biochemistry and English Literature at the University of Toronto - University of Trinity College.